Few Older Men Receiving Recommended Intensity of Active Surveillance

Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs.
Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs.

Very few older man receive the intensity of active surveillance testing recommended by major prospective active surveillance (AS) programs, a study published in the Journal of Urology has shown.1

Although major prostate cancer active surveillance programs recommend repeat testing of prostate-specific antigen (PSA) and prostate biopsy, adherence to such testing remains unknown. Therefore, researchers sought to determine whether men in the community receive the same intensity of active surveillance testing as in prospective active surveillance protocols.

For the retrospective study, researchers analyzed data from 5192 men age 66 years or older undergoing active surveillance for prostate cancer. Patients had not received curative therapy in the year after diagnosis and had undergone 1 or more postdiagnosis prostate biopsies.

Results showed that more than 80% had at least 1 PSA test per year but less than 13% received a prostate biopsy beyond the first 2 years. Patients rarely underwent MRI screening.

Researchers found that recent diagnosis and higher income were associated with higher frequency of surveillance prostate biopsy. In contrast, older age and greater comorbidity were associated with fewer biopsies. African American patients were less likely to undergo PSA testing.

The study also demonstrated that during 5 years of active surveillance, only 11.1% met the testing standards of the Sunnybrrok/PRIAS program and only 5.0% met the standards of the Johns Hopkins programs.

REFERENCE

1. Loeb S, Walter D, Curnyn C, et al. How active is active surveillance? Intensity of follow-up during active surveillance for prostate cancer in the United States [published online ahead of print March 2, 2016]. J Urol. doi:10.1016/j.juro.2016.02.2963.

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs